ArticleCureus2026
A Rare Case of Yellow Urticaria Developing During Blood Transfusion.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yellow urticaria is a rare clinical variant of urticaria characterized by yellowish wheals, typically associated with hyperbilirubinemia. Its occurrence as a transfusion-related reaction is uncommon and may mimic more serious transfusion complications. We report the case of a 15-year-old Saudi female patient who presented with prolonged vaginal bleeding and severe iron deficiency anemia requiring packed red blood cell transfusion. Approximately 15 minutes after transfusion initiation, she developed pruritic yellowish urticarial wheals over the trunk and extremities, without angioedema or hemodynamic instability. Laboratory evaluation revealed mild hyperbilirubinemia, while direct and indirect Coombs tests were negative, and no clinical or laboratory evidence suggestive of hemolysis was identified. The transfusion was temporarily interrupted, and the patient was treated with antihistamines, corticosteroids, and epinephrine, leading to complete resolution of the lesions within 24 hours. Transfusion was later resumed without recurrence. This case highlights transfusion-related yellow urticaria as a benign but rare reaction. Early recognition is essential to avoid misdiagnosis and unnecessary interruption of life-saving transfusion therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.